This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4kq3
From Proteopedia
(Difference between revisions)
| (4 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{STRUCTURE_4kq3| PDB=4kq3 | SCENE= }} | ||
| - | ===Crystal structure of Anti-IL-17A antibody CNTO3186=== | ||
| - | {{ABSTRACT_PUBMED_24470236}} | ||
| - | == | + | ==Crystal structure of Anti-IL-17A antibody CNTO3186== |
| - | [[4kq3]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KQ3 OCA]. | + | <StructureSection load='4kq3' size='340' side='right'caption='[[4kq3]], [[Resolution|resolution]] 1.92Å' scene=''> |
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4kq3]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4KQ3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4KQ3 FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MES:2-(N-MORPHOLINO)-ETHANESULFONIC+ACID'>MES</scene>, <scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4kq3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4kq3 OCA], [https://pdbe.org/4kq3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4kq3 RCSB], [https://www.ebi.ac.uk/pdbsum/4kq3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4kq3 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Three Fab structures used as targets in the Antibody Modeling Assessment presented a challenge for modeling CDR-L3 due to deviations from the most typical canonical structure. In all three antibodies CDR-L3 has eight residues, which is one residue shorter than usual, and has a conformation that is rarely observed in crystal structures. We analyzed the sequence and structural determinants of this conformation and found that the "short" CDR-L3 is remarkably rigid and retains the conformation in the interactions with antigens and neighboring CDRs. Proteins 2014. (c) 2014 Wiley Periodicals, Inc. | ||
| - | + | Structural evidence for a constrained conformation of short CDR-L3 in antibodies.,Teplyakov A, Obmolova G, Malia TJ, Luo J, Gilliland GL Proteins. 2014 Jan 27. doi: 10.1002/prot.24522. PMID:24470236<ref>PMID:24470236</ref> | |
| - | <ref | + | |
| - | [[Category: | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> |
| - | [[Category: | + | </div> |
| - | [[Category: | + | <div class="pdbe-citations 4kq3" style="background-color:#fffaf0;"></div> |
| - | [[Category: | + | == References == |
| - | [[Category: | + | <references/> |
| - | [[Category: | + | __TOC__ |
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Gilliland GL]] | ||
| + | [[Category: Malia T]] | ||
| + | [[Category: Obmolova G]] | ||
| + | [[Category: Teplyakov A]] | ||
Current revision
Crystal structure of Anti-IL-17A antibody CNTO3186
| |||||||||||
